Recently, the sulfated glucosamine capsules independently developed and produced by Qingdao Baiyang Pharmaceutical Co., Ltd. (hereinafter referred to as "Qingdao Baiyang") have been officially approved for market by the National Medical Products Administration (NMPA). The product is used for the treatment of primary and secondary osteoarthritis.

According to data, the number of osteoarthritis patients in China has exceeded 140 million. Glucosamine, as a widely used medication for the treatment of osteoarthritis, can improve joint activity and relieve pain. The approved sulfated glucosamine capsules by Qingdao Baiyang have good clinical application value and market prospects. After being launched, it will enrich Baiyang Pharmaceutical's product matrix and provide patients with high-quality and cost-effective medication choices.

Qingdao Baiyangl, as a high-end slow-release formulation research and manufacturing platform under Baiyang Pharmaceutical, focuses on the research and development, production, and sales of high-end slow-release formulations such as osmotic pumps, pellet coatings, and skeleton tablets. It has passed the cGMP (Dynamic Good Manufacturing Practice) inspection of the US Food and Drug Administration with "zero defects" and achieved simultaneous reporting and sales of multiple products in China and the United States. Previously, Qingdao Baiyang developed and produced the osmotic pump controlled release formulation metformin nida ® Entering the national medical insurance and rapidly introducing clinical practice; Celecoxib Capsules Nike ®、 Duloxetine hydrochloride enteric coated capsules ®、 Nifedipine controlled-release tablets Knight ® Compared with the sustained-release capsules of Mexicam hydrochloride, Naixin ® The product is also selected for national procurement.

In the future, Qingdao Baiyang Pharmaceutical, as a new force in China's national pharmaceutical industry, will continue to focus on the research and production of high-end formulations and innovative drugs. While improving the level of domestic drug development and clinical efficacy, it will also bring more international quality drugs with equivalent price advantages and reliable therapeutic effects to domestic patients.